Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling. by Bontekoe, Emily et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Medicine Faculty Papers Department of Medicine 
5-10-2021 
Upregulation of Inflammatory Cytokines in Pulmonary Embolism 






See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/medfp 
 Part of the Cardiology Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson 
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Emily Bontekoe, Yevgeniy Brailovsky, Debra Hoppensteadt, Jack Bontekoe, Fakiha Siddiqui, Joshua 
Newman, Omer Iqbal, Trent Reed, Jawed Fareed, and Amir Darki 
Original Article
Upregulation of Inflammatory Cytokines in
Pulmonary Embolism Using Biochip-
Array Profiling
Emily Bontekoe, BS1 , Yevgeniy Brailovsky, DO2 ,
Debra Hoppensteadt, PhD3 , Jack Bontekoe, MD1 ,
Fakiha Siddiqui, BDS1 , Joshua Newman, MD4,
Omer Iqbal, MD, FACC5, Trent Reed, DO, FACEP6,
Jawed Fareed, PhD, FAHA3 , and Amir Darki, MD7
Abstract
The complex pathophysiology of pulmonary embolism (PE) involves hemostatic activation, inflammatory processes, cellular
dysfunction, and hemodynamic derangements. Due to the heterogeneity of this disease, risk stratification and diagnosis remains
challenging. Biochip-array technology provides an integrated high throughput method for analyzing blood plasma samples for the
simultaneous measurement of multiple biomarkers for potential risk stratification. Using biochip-array method, this study aimed
to quantify the inflammatory biomarkers such as interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, vascular endothelial growth
factor (VEGF), interferon gamma (IFN-g), tumor necrosis factor alpha (TNF-a), monocyte chemoattractant protein-1 (MCP-1),
and epidermal growth factor (EGF) in 109 clinically confirmed PE patients in comparison to the control group comprised of plasma
samples collected from 48 healthy subjects. Cytokines IL-4, IL-6, IL-8, IL-10, IL-1b, and MCP-1 demonstrated varying level of
significant increase (P < 0.05) in massive-risk PE patients compared to submassive- and low-risk PE patients. The upregulation of
inflammatory cytokines in PE patients observed in this study suggest that inflammation plays an important role in the overall
pathophysiology of this disease. The application of biochip-array technology may provide a useful approach to evaluate these
biomarkers to understand the pathogenesis and risk stratification of PE patients.
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Introduction
Acute pulmonary embolism (PE) is a complex, multifactorial
disease involving both systemic and localized processes. It is
estimated nearly 600,000 Americans develop PE and deep vein
thrombosis (DTV), leading to 100,000 deaths annually.1 PE
refers to a thrombus that detaches from a DVT and obstructs
the pulmonary artery or peripheral arteries. This obstruction
occludes blood flow and consequentially increases right ven-
tricular (RV) pressure.2 Failure of the pulmonary circuit leads
to systemic hypoperfusion, hypoxia, ischemia, and eventually
death.3,4 Left untreated, PE results in a high likelihood of mor-
tality, arrhythmia, and massive RV failure.4 Even after effec-
tive treatment of acute PE, patients are at risk for developing
persistent dyspnea, exercise limitations, and impaired quality
of life.5
The diagnosis, risk-stratification, and treatment selection of
PE patients remains difficult despite advancements in diagnos-
tic approaches. As the severity of symptoms associated with PE
can vary greatly and are largely non-specific, PE diagnostic
criteria lack consensus and vary widely.6 Clinical scoring cri-
teria, such as the Geneva and Pulmonary Embolism Severity
Index (PESI) scores are useful in the prediction of adverse
outcomes of acute PE, yet do not utilize imaging nor biomar-
kers.7 Recent studies have shown biomarkers to be useful for
risk stratification, evaluation, and treatment strategies in many
cardiopulmonary disorders, yet markers specific for PE have
not been found.8 Guidelines for the management of acute PE
from the European Society of Cardiology (ESC) have found
troponin levels in patients with PE to be useful in guiding
anticoagulation therapy and classifying PE severity by subse-
quent right ventricular dysfunction and cardiac injury, yet the
question arises whether additional biomarkers would be more
useful, equivalent, or complementary to cardiac troponin lev-
els.9-12 Therefore, further development of risk stratification
criteria through the use of biomarkers may be helpful to iden-
tify PE patients at low and high risk of mortality.
The complex pathophysiology of PE involves thrombogen-
esis, inflammation, endothelial cell dysfunction, and hemody-
namic aberrations. These processes contribute to the formation,
progression and outcome of PE.4,13,14 The formation of throm-
bosis is likely due to the activation of endothelial cells, plate-
lets, and leukocytes, resulting in inflammatory cytokine release
and triggering of the coagulation system.15-17 Additionally, the
presence of an established embolism has also been shown to be
a source of inflammation.3
Inflammation and thrombosis are closely associated and can
cross activate one another.18,19 This phenomenon has been
observed in several complex hemostatic disorders, such as sep-
sis associated coagulopathy and coronavirus disease 2019
(COVID-19) associated thromboembolic complications. Pro-
inflammatory cytokines, such as IL-1b, IL-6, IL-8 and TNFa,
promote a pro-coagulant state through the induction of tissue
factor.18,19 Anti-inflammatory cytokines, including IL-2, IL-4,
and IL-10, act to reduce coagulation induced by other pro-
inflammatory factors.20 This regulation of anti-inflammatory
and pro-inflammatory cytokines is disrupted during trauma,
infection, tumors, and surgery.19 Therefore, due to the vascular
stress and thrombosis associated with PE, analyzing biomar-
kers of inflammation may aid in understanding the complex
pathophysiology of this condition.
Biochip technology provides simultaneous measurement of
multiple analytes, creating a panel from a single patient sample.
Efficient and cost-effective, this technology allows for a large-
scale and rapid evaluation of data.20 Biochips have been used to
investigate other disorders such as angina, various cancers,
neurodegenerative diseases, and pneumonia.21 Commercially
available biochip technology, such as RANDOX biochip array
approach, allows for simultaneous measurement of inflamma-
tory markers present as a result of numerous dysregulated cel-
lular processes, which may be useful in the evaluation of PE
patient plasma.20,21
This study sought to quantify the inflammatory biomarkers
interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, vas-
cular endothelial growth factor (VEGF), interferon gamma
(IFN-g), tumor necrosis factor alpha (TNF-a), monocyte che-
moattractant protein-1 (MCP-1), and epidermal growth factor
(EGF) in PE patient plasma compared to healthy controls. We
hypothesized that higher levels of pro-inflammatory biomar-
kers would correlate with greater severity scores in PE patients.
Identification of significantly elevated cytokines may provide
insight to the complex pathophysiology of PE as well as poten-
tial therapeutic targets. Additionally, correlation of cytokine
concentration to PE severity may be useful for stratification
models.
Materials and Methods
Patient Selection and Data Collection
Patients 18 years or older were recruited to participate in this
study through enrollment conducted in conjunction with an
ongoing IRB approved project by the Pulmonary Embolism
Response Team (PERT) registry. Diagnosis of acute PE was
confirmed by Computed Tomographic (CT) angiography or
ventilation/perfusion imaging. Patients were classified into
subcategories of low risk, submassive, and massive PE accord-
ing to the American College of Cardiology (ACC)/ American
Heart Association (AHA) guidelines.22 Table 1 depicts the
representative distribution of co-morbidities in PE patients,
including demographic information, collected through the
review of patient electronic medical records (EMR).
Blood Samples
Whole blood samples were drawn from patients within 24 hours
of confirmed diagnosis of acute PE and collected under an
Institutional Review Board approved protocol. Samples were
collected in 3.8% (0.109 mol/L) sodium citrate and EDTA
tubes at the time of PE diagnosis, processed for platelet-poor
plasma within 2 hours, and stored at -70C prior to analysis.
Control plasma samples from 50 healthy, non-smoking, adults,
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aged 19 to 53, were purchased from a commercially available
source (George King Biomedical, Overland Park, Kansas).
Biochip Assay
A Randox Investigator Cytokine and Growth Factors High-
Sensitivity Array was utilized to measure IL-2, IL-4, IL-6,
IL-8, IL-10, VEGF, IFN-g, TNF-a, IL-1a, IL-1b, MCP-1 and
EGF (Randox Laboratories, London, United Kingdom) per
manufacturer guidelines. Quantification of all factors were
tested simultaneously by utilizing a sandwich chemilumines-
cent immunoassay using a single patient sample.
Statistical Analysis
Circulating levels of each biomarker in PE patient plasma were
compared to control plasma. Descriptive statistics were calcu-
lated utilizing GraphPad Prism version 8.3.0 (GraphPad Soft-
ware, La Jolla, California) and Microsoft Excel version 16.0
software. Statistical difference between PE groups and normal
controls were evaluated utilizing nonparametric Mann-
Whitney t tests and Kruskal-Wallis ANOVA. Correlations uti-
lized Spearman correlation coefficients. Fold increase from the
normal mean was calculated for each individual patient and
averaged. P < 0.05 was considered statistically significant.
Results
Samples from 109 pulmonary embolism patients were used in
this study. PE patients were categorized based on guidelines
from the ACC/AHA and classified as low risk (n¼ 23; 21.1%),
submassive (n ¼ 76; 69.7%), and massive PE (n ¼ 10; 9.2%).
As shown in Figure 1, the levels of IL-4, IL-6, IL-8, IL-10,
VEGF, IFN-g, TNF-a, IL-1a, IL-1b, MCP-1 and EGF were
significantly elevated in PE patients compared to normal indi-
viduals (P < 0.05). Levels of IL-2 were not found to be signif-
icantly different between PE patients and healthy controls.
Composite data, including the average, median, and range for
each cytokine are shown in Table 2.
The mean fold difference between each individual PE sam-
ples and the normal sample mean are shown in Figure 2. Wide
variation in the average fold difference was demonstrated in the
PE population. IL-6 exhibited the highest average fold differ-
ence from the normal mean at 53-fold, followed by EGF and
IL-8 at 22 and 20-fold higher, respectively.
Table 3 provides a composite tabulation of various inflamma-
tory biomarkers in accordance to low, submassive, and massive
risk subgroups. The data is tabulated in terms of mean, median,
and range for individual biomarkers in each subgroup. Moreover,
individual differences in the range of the various biomarkers were
evident. Figure 3 shows a composite of variations in several bio-
markers for each subgroup as illustrated in graphic version. Such
biomarkers including interleukin-4, IL-6, IL-8, IL-10, IL-1b, and
MCP-1 were significantly elevated in the massive PE subgroups
compared to submassive and low-risk PE (P < 0.05). VEGF and
EGF showed downwards trends in the massive group.
Correlations between cytokine concentrations for all biomar-
kers in PE patients are shown in Table 4, with bolded values
indicating statistical correlation (P < 0.05). At least one signifi-
cant correlation was observed in all cytokines. Interleukin-8,
TNF-a, and IL-1b correlated with four additional cytokines. The
strongest correlation was observed between IL-6 and IL-8, with a
Spearman correlation coefficient of 0.555 (P < 0.0001).
Discussion
Pulmonary embolism is a complex, multifactorial disease
involving dysregulation in coagulation, fibrinolysis, and inflam-
matory processes, as well as hemodynamic insults and vascular
cellular injury. Due to the difficulty in diagnosis and risk stratifi-
cation, analyzing biomarkers involved in the pathophysiology
of PE may allow for additional disease characterization. We
have previously reported on the dysregulation of thrombo-
inflammatory biomarkers in sepsis.22 The markedly higher
level of these biomarkers in the sepsis group are indicative
of severe inflammatory response, as observed in the PE
patients. Relative elevation of these markers may vary in
other pathophysiologic states such as viral pneumonias,
trauma, and unprovoked PE. Thus, utilizing biochip array
technology allows for a comprehensive biochemical quanti-
fication to underscore the multifaceted processes involved in
this disease.
Our study found significantly higher levels of both pro-
inflammatory and anti-inflammatory biomarkers in PE patients
compared to healthy controls, indicating the high amounts of
cellular dysfunction and inflammation associated with PE. We
speculated that these processes play complex roles within this
Table 1. Representative Distribution of Co-Morbidities in Pulmonary
Embolism Patients.a
Age (mean + standard deviation) 62.8 + 14.8
Female, n (%) 66 (60.5%)
Race
White, n (%) 55 (50.4%)
Black, n (%) 47 (42.1%)
Hispanic, n (%) 2 (1.8%)
Other, n (%) 5 (4.5%)
Body mass index (kg/m2, median + IQR) 32.6 (26.5-37.9)
PESI score (median + IQR) 117 (81-149)
Hypertension, n (%) 62 (56.8%)
Diabetes mellitus, n (%) 20 (18.3%)
Chronic kidney disease, n (%) 23 (21.1%)
Cancer, n (%) 28 (25.6%)
Coronary artery disease, n (%) 13 (11.9%)
COPD, n (%) 12 (11%)
Prior stroke, n (%) 7 (6.4%)
Prior pulmonary embolism, n (%) 13 (11.9%)
Acute DVT, n (%) 68 (62.3%)
Lactate (median + IQR) 1.7 (1.1-2.2)
Abbreviations: PESI, pulmonary embolism severity index; COPD, chronic
obstructive pulmonary disease; DVT, deep vein thrombosis; IQR, interquartile
range.
aThe above analysis of the co-morbidities and demographic is based on the
available data on 60 patients representing the cohort analyzed.
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condition, thus increased concentrations of biomarkers associ-
ated with cellular dysfunction and inflammation as seen in this
study would be expected to correlate with a higher PE severity
and an overall systemic stress response. Increased intensity of
inflammation associated with acute PE likely correlates with
morbidity and mortality and may contribute to the poorer
chronic health outcomes in these patients following PE resolu-
tion. Inflammation can also lead to activation of other systemic
processes, such as coagulation and fibrinolysis, endothelial
dysfunction, and hemodynamic changes, which also may con-
tribute to the pathogenesis and propagation of this disease.
The cytokines demonstrating the largest average fold
increase relative to healthy normals included IL-6, IL-8, and
EGF. Interleukin-6 is a major pro-inflammatory cytokine
linked to DVT progression.23 The general mechanism of IL-6
is well understood and has been known to be closely related to
tissue damage through inflammation, endothelial cell and pla-
telet activation, and promoting coagulation without affecting
fibrinolysis.7 Elevated levels of IL-6 seen in PE patients
increase the ability of platelets to respond to thrombin and thus
promote the development of thrombosis.19,24 This may explain
the significantly increased levels of IL-6 observed in massive
Figure 1. Comparison of cytokine levels between PE patients (n ¼ 109) and healthy individuals (n ¼ 48). Data is represented as mean + SEM.
*P < 0.05. PE indicates pulmonary embolism; SEM, standard error of mean.
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PE patients, compared to low-risk and submassive patients,
since these patients have a more severe embolic event. Thus, our
results suggest IL-6 may be useful in stratifying PE severity.
Interleukin-8 promotes the expression of integrins on the
vascular endothelium and allowing for adhesion of neutrophils25
and monocytes.26 Integrin expression thus alters the homeostatic
role of the endothelium to prevent clot formation. Previous stud-
ies have shown IL-8 to be involved in procoagulant activity27,28
and elevated levels have been shown to correlate with first throm-
botic events; elevated levels of this biomarker may be a risk factor
for venous thrombosis.29,30 Our study demonstrated significantly
elevated levels of IL-8 in all PE patients compared to healthy
individuals, and additionally, patients with massive PE to have
significantly higher levels compared to low-risk and submassive
patients. Therefore IL-8 elevation may be a potential indicator of
thrombosis development. These results are supportive of previous
research suggesting that IL-8 expression leads to thrombosis and
therefore may be indicative of embolism severity.30
Additionally, this study found significantly elevated levels
of EGF in PE patients compared to healthy controls. Studies
have shown that particles of EGF, known as signal peptide-
complement C1r/C1 s, Uegf, and Bmp1-EGF domain-
containing protein 1 (SCUBE1) to be higher in the PE population
compared to non-PE and control groups.31,32 Despite trends
towards higher levels, significance was not reached among risk
classifications. As epidermal growth factor is a prominent
protein released from activated platelets during thrombus
formation,33 a possible explanation for the generalized higher
levels of EGF seen in the PE population may be due to platelet
activation involved in the formation of embolic lesions.
Additionally, the cytokines IL-4, IL-6, IL-8, IL-10, IL-1b,
and MCP-1 were all significantly elevated in massive PE
patients in comparison to those with low-risk and submassive
disease, indicating the overwhelming inflammatory response
with larger embolism. Amongst the cytokines analyzed, IL-2
was the only biomarker which was not significantly elevated in
PE patient plasma compared to normal controls. IL-2 is known
to be involved in suppressing the inflammatory response, and
thus a non-significant elevation of this biomarker in our study
may reflect dysregulation in the anti-inflammatory cascade in
PE patients.
Most patients included in our study represent those recruited
in PERT study with acute PE due to multiple factors including
preexisting DVT, cancer, trauma, and surgical interventions.
None of the patients had COVID-19. Because of the hetero-
genous nature of our group, it is likely that some patients had
preexisting increase in various biomarkers. The availability of
such data will be helpful in further characterization of the
pathophysiology of acute PE.
Correlations between these cytokines were demonstrated in
this population, as shown in Table 4, and indicate a complex
interconnection between multiple pathways within the inflam-
matory response of PE. The strongest correlation in this study
was observed between IL-6 and IL-8, which further
Table 2. Inflammatory Biomarker Levels in PE Patients and Healthy Controls.
PE patients (n ¼ 109) Healthy controls (n ¼ 48)
Marker Mean + SEM (pg/ml) Median (pg/ml) Range (pg/ml) Mean + SEM (pg/ml) Median (pg/ml) Range (pg/ml)
IL-2 1.27 + 0.21 1.03 0-19.9 1.11 + 0.26 0 0-6.25
IL-4 1.83 + 0.05 1.74 0-4.62 1.28 + 0.16 1.41 0-6.73
IL-6 65.8 + 13.3 17.73 0.59-1003 1.25 + 0.18 0.94 0.25-7.29
IL-8 52.8 + 12.1 11.79 1.45-692 2.64 + 0.13 2.585 0.985.74
IL-10 4.97 + 1.64 0.9 0-131.24 0.68 + 0.05 0.6 0-2.12
VEGF 25.7 + 3.27 13.47 2.36-219.7 4.78 + 0.19 4.585 2.14-7.77
IFNg 0.33 + 0.04 0.23 0-2.52 0.17 + 0.04 0 0-1.76
TNFa 2.72 + 0.32 1.99 0-33.63 1.73 + 0.15 1.77 0-6.55
IL-1a 0.19 + 0.01 0.16 0-0.83 0.10 + 0.02 0.1 0-0.53
IL-1b 1.51 + 0.19 1.21 0-17.48 0.79 + 0.18 0 0-5.63
MCP-1 170 + 15.2 129.87 7.79-746 88.60 + 3.93 90.38 30.22-149.52
EGF 30.6 + 3.24 19.95 0.51-216 1.36 + 0.17 1.265 0-5.42
Abbreviations: EGF, epidermal growth factor; IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor; VEGF,
vascular endothelial growth factor.
Figure 2. Fold increase of inflammatory biomarkers in PE patients
compared to the normal mean. Data is represented as mean + SEM.
PE indicates pulmonary embolism; SEM, standard error of mean.
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underscores the importance of these cytokines in the progres-
sion of the severity of the observed pathogenesis of PE. Future
studies investigating biomarker concentrations in relation to
patient outcomes, such as mortality and long-term outcomes
would be of interest. Additionally, assessing a combination of
these biomarkers along with cardiac troponins may further
facilitate the prediction of disease outcomes. Furthermore, eva-
luation of these biomarkers in patients following PE resolution
may provide insight to the duration of inflammation and may
be useful for guiding pharmacological and pharmaco-
mechanical treatments and their effectiveness. The biochip
array profile used in this study provides a high throughput
technology with reproducibility and reliable sensitivity. The
upper and lower limit of quantification have been established and
the data generated in several studies was within these limits.
The biomarker profiling in COVID-19 patients with pul-
monary manifestations has also validated the diagnostic and
prognostic value of the biomarkers investigated in our study.34
There is a growing awareness of the increased prevalence of PE
in COVID-19 patients. Evaluation of biomarkers in COVID-19
patients can help in risk stratification and prediction of the
clinical outcome in these patients.35 The hemostatic abnormal-
ities in COVID-19 result in complex thrombotic complications,
including PE, and are associated with increased inflammatory
and/or thrombotic cytokines. PE eventually contributes to the
intravascular coagulopathy associated with marked increase in
D-dimer, fibrin-degradation products, and endothelial dysfunc-
tion.36 Profiling of biomarkers in COVID-19 patients is also
helpful in the anticoagulant management of these patients, par-
ticularly those with PE and its complications. It is indeed true
that COVID-19 associated PE also manifests other vascular
co-morbidities. However, biomarker quantification provides
comparable information on the dysregulation of hemostatic pro-
cesses and the increased thrombo-inflammatory state observed
in PE.37,38 The biomarkers measured in our study were primarily
comprised of inflammatory cytokines. Similar multiparametric
biochip analyses can also be developed for coagulation activa-
tion, fibrinolytic dysregulation, and platelet release products.
Dedicated instruments with rapid turnaround and onsite monitor-
ing will be developed to manage these critically ill patients with
COVID-19 and other conditions resulting in PE.
Study Limitations
As this study was observational, there are limitations to the
applicability of these results in risk stratification. We did not
follow these patients long-term and therefore are unable to
correlate circulating levels of these biomarkers to clinical out-
comes over periods of time. Additionally, as blood samples
were collected at a single time, serial measurements of these
biomarkers throughout resolution and treatment of PE may be
useful to provide insight to the efficacy or dysregulation of
inflammatory and hemostatic responses within this condition.
In our study, we were not able to stratify the patient group in
accordance to their smoking status in comparison to the con-
trol, which were non-smokers. Therefore, the role of smoking
in modulating these biomarkers is not discussed. In future stud-
ies, such stratification will be helpful. Additionally, the date
reported is based on only 109 representative cases which are
further subcategorized into three groups. Therefore, a similar
study with a larger cohort would balance subgroups and may
provide further validation of the reported observations in our
study. As noted previously, the difficulty of categorizing PE
patients into massive, submassive, and low-risk may have had
an impact in scoring the PE patients that participated in this
study, yet utilizing the PE response team (PERT) and available
guidelines, we hope to provide applicable definitions for the
maximum utility of these results. This study represented a pilot
investigation and the results warrant a need for addition trials in
a larger cohort of patients.
Table 3. Inflammatory Biomarker Levels in PE Patients According to Low, Submassive and Massive Risk.




















IL-2 0.73 + 0.15 0.99 0-2.10 1.42 + 0.30 1.03 0-19.9 1.37 + 0.33 1.16 0-3.38
IL-4 1.66 + 0.09 1.71 0-2.13 1.82 + 0.07 1.71 0-4.62 2.30 + 0.21 1.98 1.81-3.67
IL-6 45.02 + 22.23 9.32 0.87-516.7 46.41 + 9.99 17.73 0.59-594 265.12 + 97.6 191.26 2.27-1003
IL-8 53.96 + 27.94 9.62 2.49-626.1 44.57 + 12.66 10.24 1.45-692 115.2 + 65.44 49.66 10.36-692
IL-10 2.72 + 1.42 0.61 0-32.9 1.56 + 0.22 0.88 0-10.54 36.03 + 14.83 15.03 0.4-131
VEGF 25.46 + 6.62 15.83 2.77-150.7 25.55 + 4.11 13.2 2.36-219 18.84 + 5.25 15.81 3.69-55.56
IFNg 0.33 + 0.07 0.23 0-1.23 0.35 + 0.05 0.24 0-2.52 0.27 + 0.12 0.12 0-0.99
TNFa 3.55 + 1.42 1.79 0.9-33.63 2.36 + 0.15 1.99 0-6.34 3.40 + 0.68 2.55 1.71-8.66
IL-1a 0.19 + 0.02 0.16 0-0.48 0.18 + 0.01 0.15 0-0.61 0.35 + 0.10 0.26 0-0.83
IL-1b 1.74 + 0.74 1.04 0-17.5 1.30 + 0.13 1.18 0-7.03 2.61 + 0.54 2.12 0.97-6.11
MCP-1 142.8 + 16.3 125.75 28.4-334.8 149.53 + 16.7 126.84 7.79-746 397.6 + 72.9 421.41 57.18-746
EGF 34.09 + 7.18 19.56 1.05-134.1 30.05 + 4.05 19.95 0.51-216 21.23 + 5.15 19.57 0.61-56.28
Abbreviations: EGF, epidermal growth factor; IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor; VEGF,
vascular endothelial growth factor.
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Conclusion
The primary purpose of this study was to quantify inflamma-
tory cytokine levels in pulmonary embolism patient plasma
according to patient risk categorization of low-, submassive-,
and massive-risk based on the ACC/AHA guidelines.22 Bio-
chip array technology was used for the quantification of mul-
tiple inflammatory cytokines simultaneously. This study
demonstrated an elevated systemic inflammatory response due
to the elevation in anti-inflammatory and pro-inflammatory
cytokines, including IL-4, IL-6, IL-8, IL-10, VEGF, IFN-g,
TNF-a, IL-1a, IL-1b, MCP-1 and EGF in PE patients compared
to healthy individuals. IL-2 was the only biomarker found to not
reach significance in the PE population compared to controls.
These results demonstrate that increased inflammation is associ-
ated with increased PE severity, allowing us to speculate that the
pathogenesis of this condition largely involves multiple inflam-
matory processes. The use of biochip array technology may be a
valuable and efficient means to evaluate multiple inflammatory
markers and allow for rapid evaluation of these biomarkers for the
use of guiding clinical decisions. The biochip array technology
described in these studies can also be expanded to evaluate bio-
markers of hemostatic dysregulation and immuno-activation.
Future studies aimed in correlating these results to clinical out-
comes may be useful for the evaluation of patients long term and
provide additional insight to the pathogenesis of this condition.
Figure 3. Comparison of cytokine levels in PE patients with low, submassive, and massive PE risk. Data is represented as mean + SEM. *P <
0.05. PE indicates pulmonary embolism; SEM, standard error of mean.
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